What President Clinton or President Trump Will Mean for Biotech and Pharma

This past June, a STAT news article described the current presidential race as between a "policy wonk and a 'black box'" in other words Clinton's track record shows somewhat elaborate strategies that haven't always been successful while Trumps' views on biotech are "an almost complete mystery". Of the two Clinton is probably perceived at the most knowledgeable in regards to the biotech industry, STAT wrote: "Even Clinton’s conservative critics don’t doubt her knowledge — but they object to her proposed solutions, including her plan to crack down on drug prices, which they say fails to appreciate the financial risks biotech investors have to take." Regardless of Clinton's reputation of cracking down on drug prices, Boston Business Journal has reported that the majority of political contributions from biotech executives in the Boston area have been for Clinton (not a big surprise in a blue state).

Get an expert, up-to-the-minute view on what Clinton and Trump will mean for biotech and pharma at Biotech Week Boston's STAT Panel Discussion: President Clinton or President Trump: What Our Next President Will Mean For Biotech and Pharma this October. This panel will feature: Rick Berke, Executive Editor of STAT; Dylan Scott, Washington Correspondent at STAT; Damien Garde, National Biotech Reporter at STAT; Mason Tenaglia, Vice President at IMS Institute for Healthcare Informatics; David Meeker, Executive Vice President and Head of Sanofi Genzyme; and Kathleen Weldon Tregoning, Senior Vice President, Corporate Affairs at Biogen.

For a sneak peak, here's what Mason Tenaglia, Vice President of IMS Institute for Healthcare Informatics had to say in Pharmaceutical Executive about the challenges facing pharma from increased scrutiny due to the elections: “Due to the increased presence of pharmacy deductibles, patients are being exposed to the ‘raw, naked’ price of mainstream drugs like insulins, LABA, DPP4, and others.” This leads to the situation where “the pharmacy passes these on at ‘full price’ when the payer probably is getting a 40% rebate,”... 2016 “might be the year when all pricing heuristics disappear and pharma companies lower their list prices for new launches while holding back on rebates to the payers.”

Learn more about #BiotechWeekBoston

Share this article with your social network, just click below to share now!

Share |